ArticleRheumatology international2026
Machine learning improves online self-referral for inflammatory rheumatic diseases: a registry-based validation study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Referral delays and errors in inflammatory rheumatic diseases (IRDs) are common. RhePort is a German online self-referral tool that estimates IRD probability based on a structured questionnaire and expert-derived algorithm. This study evaluated whether machine learning could improve IRD discrimination of RhePort. In this retrospective internal validation study, 1,333 unique RhePort questionnaires linked to rheumatologist-confirmed diagnoses were analyzed. A shared stratified five-fold cross-validation design was used for Logistic Regression, Neural Network, XGBoost, and LightGBM models. For each algorithm, feature selection and Bayesian hyperparameter optimization were performed, followed by evaluation of ensemble strategies. Discrimination, calibration, clinically relevant operating points, and SHAP-based interpretability were assessed against the original RhePort score. IRD prevalence was 35.6% (475/1,333). LightGBM achieved the strongest individual performance, with an area under the receiver operating characteristic curve of 0.791 using 30 features. A weighted ensemble of LightGBM and Logistic Regression further improved performance to 0.815 and achieved the lowest Brier score (0.166). At 95% sensitivity, specificity increased from 9% for RhePort to 32%; at 90% sensitivity, specificity increased from 15% to 48%. The most influential predictors included C-reactive protein, painful small joints, dactylitis pattern, sex, and erythrocyte sedimentation rate. Ensemble AUC-ROC was 0.828 among 746 patients with CRP and/or ESR information and 0.786 among 587 patients without these laboratory data. Machine learning improved IRD classification over the current expert-derived RhePort score and identified questionnaire items that may be omitted without loss of performance, demonstrating the potential of machine learning to enhance rheumatology referral.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.